The authors report on their observations with the treatment of premenstrual syndrome with gestogens of different dosage. The efficacy of medroxyprogeszteron-acetate therapy with 20 mg/die and 40 mg/die between the 15. and 26. days of menstruation were studied with the help of the premenstrual syndrome index. The connection between the efficacy and dosage of the efficacy and period of therapy were observed. According to the data the elevated dosage of medroxyprogeszteron-acetate does not increase the efficacy of therapy. After 3 month treatment period 67% of the complaints disappeared. Further therapy does not increase efficacy, but has been important to prevent remissions. According to the data of this study the authors opinion is that a dosage of 20 mg/die medroxyprogeszteron-acetate treatment between the 15. and 26. days of menstrual cycle is sufficient to treat premenstrual syndrome.